FOXP1

FOXP1

History

%%{init: { 'logLevel': 'debug', 'theme': 'dark' } }%%
timeline
    title Publication timing
      2017-10-10 : Reddy : DLBCL

Loading

Relevance tier by entity

Entity	Tier	Description
	2-a	aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous

Mutation incidence in large patient cohorts (GAMBL reanalysis)

Entity	source	frequency (%)
DLBCL	GAMBL genomes	0.57
DLBCL	Schmitz cohort	3.62
DLBCL	Reddy cohort	2.10
DLBCL	Chapuy cohort	2.99

Mutation pattern and selective pressure estimates

Entity	aSHM	Significant selection	dN/dS (missense)	dN/dS (nonsense)
BL	Yes	No	1.218	9.469
DLBCL	Yes	No	7.387	17.777
FL	Yes	No	0.000	0.000

aSHM regions

chr_name	hg19_start	hg19_end	region	regulatory_comment
chr3	71104986	71119518	TSS-4	active_promoter
chr3	71176427	71180960	TSS-3	active_promoter
chr3	71350633	71357665	TSS-2	active_promoter
chr3	71503103	71504870	intron-1b	intron
chr3	71550753	71551478	intron-1a	intron
chr3	71626341	71635648	TSS-1	active_promoter

View coding variants in ProteinPaint hg19 or hg38


View all variants in GenomePaint hg19 or hg38

FOXP1 Expression

References

1. Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W, Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y, Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O, Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB, Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T, Rajagopalan D, Datta J, Dunson DB, Dave SS. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell. 2017 Oct;171(2):481-494.e15.